Delirious After Undergoing Workup for Stroke Veeraraghavan Iyer, MBBS, MD, and Douglas Opler, MD

Total Page:16

File Type:pdf, Size:1020Kb

Delirious After Undergoing Workup for Stroke Veeraraghavan Iyer, MBBS, MD, and Douglas Opler, MD Cases That Test Your Skills Delirious after undergoing workup for stroke Veeraraghavan Iyer, MBBS, MD, and Douglas Opler, MD Ms. L, age 91, experiences acute altered mental status after How would you undergoing routine evaluation of an episode of left-sided handle this case? Answer the challenge weakness. What could be causing her symptoms? questions at MDedge.com/ psychiatry and see how your colleagues responded CASE Altered mental status after Which laboratory and/or imaging tests should stroke workup Ms. L undergo next? Ms. L, age 91, is admitted to the hospi- a) repeat BUN and creatinine levels tal for a neurologic evaluation of a recent b) urinalysis and comprehensive metabolic episode of left-sided weakness that profile occurred 1 week ago. This left-sided weak- c) repeat CT scan of the head ness resolved without intervention within d) diffusion-weighted MRI 2 hours while at home. This presentation e) blood culture for signs of infection is typical of a transient ischemic attack (TIA). She has a history of hypertension, bradycardia, and pacemaker implanta- The authors’ observations tion. On initial evaluation, her memory Due to her acute altered mental status is intact, and she is able to walk normally. (AMS), Ms. L underwent an emergent Her score on the St. Louis University Mental CT scan of the head to rule out any acute Status (SLUMS) exam is 25, which suggests intracranial hemorrhages or thromboem- normal cognitive functioning for her aca- bolic events. The results of this test were demic background. A CT scan of the head negative. Urinalysis, BUN, creatinine, basic reveals a subacute stroke of the right poste- chemistry, and complete blood count pan- rior limb of the internal capsule consistent els were unrevealing. On a repeat SLUMS with recent TIA. exam, Ms. L scored 9, indicating cognitive Ms. L is admitted for a routine stroke impairment. workup and prepares to undergo a CT Ms. L also underwent a comprehensive angiogram (CTA) with the use of the metabolic profile, which excluded any iodinated agent iopamidol (100 mL, 76%) electrolyte abnormalities, or any hepatic to evaluate patency of cerebral vessels. or renal causes of AMS. There was no sign Her baseline blood urea nitrogen (BUN) of dehydration, acidosis, hypoglycemia, and creatinine levels are within normal hypoxemia, hypotension, or bradycardia/ limits. Dr. Iyer is a PGY-4 resident, and Dr. Opler is Assistant Professor of A day after undergoing CTA, Ms. L starts Psychiatry, Rutgers New Jersey Medical School, Newark, New Jersey. mumbling to herself, has unpredictable Disclosures mood outbursts, and is not oriented to time, The authors report no financial relationships with any company whose products are mentioned in this article, or with manufacturers Current Psychiatry place, or person. of competing products. Vol. 18, No. 1 43 Cases That Test Your Skills Figure 1 were unable to conduct Radiologic findings of subarachnoid contrast this test because Ms. L had 2 enhancement a pacemaker. Barber et al suggested that in the set- ting of acute stroke, the use of MRI may not have an added advantage over the CT scan of the head. Which of the following is the most likely diagnosis for Ms. L? Clinical Point a) post-ictal phenomenon A B b) new-onset ischemic Delayed reactions changes to contrast agents c) contrast-induced involve a T-cell encephalopathy mediated response d) new-onset that most commonly hemorrhagic changes e) hyperperfusion results in pruritus and syndrome urticaria C D TREATMENT Rapid improvement with supportive therapy Intravenous fluids are tachycardia. A urinalysis, chest X-ray, administered as supportive therapy to Ms. L complete blood count, and 2 blood cul- for suspected contrast-induced encephalopa- tures conducted 24 hours apart did not thy (CIE). The next day, Ms. L experiences a reveal any signs of infection. There were notable improvement in cognition, beyond no recent changes in her medications that attributed to IV hydration. By 3 days post- and she was not taking any sleep medi- contrast injection, her SLUMS score increases cations or other psychiatric medications to 15. By 72 hours after contrast administra- that might precipitate a withdrawal tion, Ms. L’s cognition returns to baseline. She syndrome. is monitored for 24 hours after returning to There have been multiple reports baseline cognitive functioning. After observ- of contrast-induced nephropathy (CIN), ing her to be in no physical or medical distress which may be evidenced by high and at baseline functioning, she is discharged BUN-to-creatinine ratios and could cause home under the care of her son with outpa- Discuss this article at AMS in geriatric patients. However, CIN tient follow-up and rehab services. www.facebook.com/ was ruled out as a potential cause in our MDedgePsychiatry patient because her BUN-to-creatinine was unremarkable. The authors’ observations Routine EEG was clinically inconclusive. For Ms. L, the differential diagnosis Diffusion-weighted MRI may have been included post-ictal phenomenon, new- helpful to identify ischemic strokes that a onset ischemic or hemorrhagic changes, Current Psychiatry 44 January 2019 CT scan of the head might miss,1 but we hyperperfusion syndrome, and CIE. Cases That Test Your Skills Seizures were ruled out because EEG Figure 2 was inconclusive, and Ms. L did not have CT scan of the head showing the clinical features one would expect in prior chronic hypodensity an ictal episode. Transient ischemic attack is, by definition, an ischemic event with clinical return to baseline within 24 hours. Although a CT scan of the head may not be the most sensitive way to detect early isch- emic changes and small ischemic zones, the self-limiting course and complete resolution of Ms. L’s symptoms with return to baseline is indicative of a more benign pathology, such as CIE. New hemorrhagic conversions Clinical Point have a dramatic presentation on radiologic studies. Historically, CIE presentations on Patients may be at imaging have been closely associated with increased risk for the hyperattentuation seen in subarachnoid contrast reactions if hemorrhage (SAH). The absence of typical they have asthma, radiologic and clinical findings in our case arrhythmias, or ruled out SAH. hyperthyroidism Typical CT scan findings in CIE include abnormal cortical contrast enhancement such dyes. As a general rule, contrast agent and edema, subarachnoid contrast enhance- reactions can be categorized as immediate ment, and striatal contrast enhancement (<1 day) or delayed (1 to 7 days after contrast (Figure 1 [page 44], Figure 2, and Figure 3 administration). Immediate reactions are [page 46]). Since the first clinical description, immunoglobulin E (IgE)-mediated anaphy- reports of 39 CT-/MRI-confirmed cases of lactic reactions. Delayed reactions involve a CIE have been published in English lan- T-cell mediated response that ranges from guage medical literature, with documented pruritus and urticaria (approximately 70%) clinical follow-up3 and a median recovery to cardiac complications such as cardiovas- time of 2.5 days. In a case report by Ito et cular shock, arrhythmia, arrest, and Kounis al,4 there were no supportive radiographic syndrome. Other less prevalent complica- findings. Ours is the second documented tions include hypotension, bronchospasm, case that showed no radiologic signs of and CIN. Patients with the following factors CIE. With a paucity of other etiologic evi- may be at higher risk for contrast-induced dence, negative lab tests for other causes of reactions: delirium, and the rapid resolution of Ms. L’s • asthma AMS after providing IV fluids as support- • cardiac arrhythmias ive treatment, a temporal correlation can • central myasthenia gravis be deduced, which implicates iodine-based • >70 years of age contrast as the inciting factor. • pheochromocytoma • sickle cell anemia Iodine-based contrast agents have been • hyperthyroidism used since the 1920s. Today, >75 million pro- • dehydration cedures requiring iodine dyes are performed • hypotension. annually worldwide.5 This level of routine Although some older literature reported iodine contrast usage compels a mention of correlations between seafood and shellfish Current Psychiatry risk factors and complications from using allergies and iodine contrast reactions, Vol. 18, No. 1 45 Cases That Test Your Skills Figure 3 CT scan of the head showing lack of contrast enhancement A B Clinical Point Encephalopathy has been documented after administration of iopromide, iohexol, ioxilan, and metrizamide more recent reports suggest there may not the endothelial cells to shrink and to sepa- be a direct correlation, or any correlation rate at tight junctions directly affecting at all.5,6 the blood-brain barrier. Alternatively, the Iodinated CIE is a rare complication of increase in intraluminal pressure caused contrast angiography. It was first reported by injection of the contrast agent, in con- in 1970 as transient cortical blindness after cert with contrast agent-induced cere- coronary angiography.7 Clinical mani- bral vasodilatation, might contribute to festations include encephalopathy evi- increasing vascular wall tension, further denced by AMS, affected orientation, and separating tight junctions. A third theory acute psychotic changes, including para- suggests that vesicular transport may be noia and hallucinations, seizures, cortical a mechanism of osmotic barrier open- blindness, and focal neurologic deficits. ing. Further studies would be required to Neuroimaging has been pivotal in con- investigate these mechanisms. firming the diagnosis and in excluding Regardless of the mechanism, all the thromboembolic and hemorrhagic compli- above-mentioned studies note a rever- cations of angiography.8 sal of radiologic and neurologic findings Encephalopathy has been documented without any deficits within 48 to 72 hours after administration of iopromide,9,10 (median recovery time of 2.5 days).3 All iohexol,11 ioxilan,4 and metrizamide. The reported cases of CIE, including ours, were mechanism of neurotoxicity is unclear, found to be completely reversible without but several theories have been formu- any neurologic or radiologic deficits after lated.
Recommended publications
  • Intrathecal Gadolinium-Enhanced MR Cisternography in the Evaluation Of
    Intrathecal Gadolinium-Enhanced MR ORIGINAL RESEARCH Cisternography in the Evaluation of CSF Leakage H. Selcuk BACKROUND AND PURPOSE: Radiologic identification of the location of the CSF leakage is important S. Albayram for proper surgical planning and increases the chance of dural repair. This article describes our experience in analyzing clinically suspected cranial CSF fistulas by using MR imaging combined with H. Ozer the intrathecal administration of a gadolinium-based contrast agent. S. Ulus MATERIALS AND METHODS: A total of 85 consecutive patients with suspected CSF fistulas who G.Z. Sanus presented with persistent or intermittent rhinorrhea or otorrhea lasting for more than 1 month between M.Y. Kaynar 2003 and 2007 were included in this study. N. Kocer RESULTS: We observed objective CSF leakage in 64 of 85 patients (75%). The CSF leak was located C. Islak in the ethmoidal region in 37 patients (58%), in the superior wall of the sphenoid sinus in 8 patients (13%), in the posterior wall of the frontal sinus in 10 patients (15%), in the superior wall of the mastoid air cells in 6 patients (9%), and from the skull base into the infratemporal fossa in 1 patient (2%). Two patients (3%) showed leakage into Ͼ1 paranasal sinus. CONCLUSIONS: MR cisternography after the intrathecal administration of gadopentate dimeglumine represents an effective and minimally invasive method for evaluating suspected CSF fistulas along the skull base. It provides multiplanar capabilities without risk of radiation exposure and is an excellent approach to depict the anatomy of CSF spaces and CSF fistulas. SF leakage implies abnormal communication between the using this technique.19,20 In addition, the combination of CT Csubarachnoid space and the nasal or middle ear cavity.
    [Show full text]
  • MDCT and Contrast Media: What Are the Risks?
    071_078_00_Thomsen:Thomsen 13-02-2008 9:32 Pagina 71 MDCT and Contrast Media: What are the Risks? Henrik S. Thomsen Department of Diagnostic Radiology, Copenhagen University Hospital Herlev, Herlev Department of Diagnostic Sciences, Faculty of Health Sciences, University of Copenhagen, Denmark Introduction Renal Adverse Reactions With the advent of multi-detector computed to- Contrast-material-induced kidney damage is imme- mography (MDCT) technology, the number of pa- diate, starting as soon as the first CM molecule reach- tients undergoing contrast-enhanced CT (CECT) es the kidney; however, it takes several hours or days studies has steadily grown in the last 6 years. In for a deterioration of renal function to be detected. 2005, approximately 22 million CECT examinations Despite more than 30 years of research, the patho- were carried out in the European Union, and 32 mil- physiology of CM-induced nephropathy (CIN) is lion in the United States (The Imaging Market Guide poorly elucidated. Nonetheless, several risk factors 2005. Arlington Medical Resources, Inc., Philadel- are well-known and can be divided into CM- and pa- phia, PA). Unfortunately, post-contrast-material-re- tient-related factors. lated adverse events, i.e., all those unintended and unfavorable signs, symptoms, or diseases temporally associated with the use of an iodinated contrast ma- Contrast-Medium-Related Factors terial (CM), are a common occurrence in radiology departments. Most adverse events occur within the More than 25 years ago, Barrett and Carlisle [1] first 60 min following CM administration (“imme- showed that the incidence of CIN is significantly diate” or “acute” adverse events), with the greatest higher after the administration of high-osmolarity risk in the first 20 min.
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The
    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • ACR Manual on Contrast Media – Version 9, 2013 Table of Contents / I
    ACR Manual on Contrast Media Version 9 2013 ACR Committee on Drugs and Contrast Media ACR Manual on Contrast Media – Version 9, 2013 Table of Contents / i ACR Manual on Contrast Media Version 9 2013 ACR Committee on Drugs and Contrast Media © Copyright 2013 American College of Radiology ISBN: 978-1-55903-012-0 Table of Contents Topic Last Updated Page 1. Preface. V9 – 2013 . 3 2. Introduction . V7 – 2010 . 4 3. Patient Selection And Preparation Strategies . V7 – 2010 . 5 4. Injection of Contrast Media . V7 – 2010 . 13 5. Extravasation Of Contrast Media . V7 – 2010 . 17 6. Allergic-Like And Physiologic Reactions To Intravascular Iodinated Contrast Media . V9 – 2013 . 21 7. Contrast Media Warming . V8 – 2012 . 29 8. Contrast-Induced Nephrotoxicity . V8 – 2012 . 33 9. Metformin . V7 – 2010 . 43 10. Contrast Media In Children . V7 – 2010 . 47 11. Gastrointestinal (GI) Contrast Media In Adults: Indications And Guidelines V9 – 2013 . 55 12. Adverse Reactions To Gadolinium-Based Contrast Media . V7 – 2010 . 77 13. Nephrogenic Systemic Fibrosis . V8 – 2012 . 81 14. Treatment Of Contrast Reactions . V9 – 2013 . 91 15. Administration Of Contrast Media To Pregnant Or Potentially Pregnant Patients . V9 – 2013 . 93 16. Administration Of Contrast Media To Women Who Are Breast-Feeding . V9 – 2013 . 97 Table 1 – Indications for Use of Iodinated Contrast Media . V9 – 2013 . 99 Table 2 – Organ and System-Specific Adverse Effects from the Administration of Iodine-Based or Gadolinium-Based Contrast Agents. V9 – 2013 . 100 Table 3 – Categories of Acute Reactions . V9 – 2013 . 101 Table 4 – Treatment of Acute Reactions to Contrast Media in Children . V9 – 2013 .
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Injection of Contrast Media V7 – 2010 13 5
    ACR Manual on Contrast Media Version 8 2012 ACR Committee on Drugs and Contrast Media ACR Manual on Contrast Media Version 8 2012 ACR Committee on Drugs and Contrast Media © Copyright 2012 American College of Radiology ISBN: 978-1-55903-009-0 Table of Contents Topic Last Updated Page 1. Preface. V8 – 2012 . 3 2. Introduction . V7 – 2010 . 4 3. Patient Selection and Preparation Strategies . V7 – 2010 . 5 4. Injection of Contrast Media . V7 – 2010 . 13 5. Extravasation of Contrast Media . V7 – 2010 . 17 6. Adverse Events After Intravascular Iodinated Contrast Media . V8 – 2012 . 21 Administration 7. Contrast Media Warming . V8 – 2012 . 29 8. Contrast-Induced Nephrotoxicity . V8 – 2012 . 33 9. Metformin . V7 – 2010 . 43 10. Contrast Media in Children . V7 – 2010 . 47 11. Iodinated Gastrointestinal Contrast Media in Adults: Indications . V7 – 2010 . 55 and Guidelines 12. Adverse Reactions to Gadolinium-Based Contrast Media . V7 – 2010 . 59 13. Nephrogenic Systemic Fibrosis (NSF) . V8 – 2012 . 63 14. Treatment of Contrast Reactions . V8 – 2012 . 73 15. Administration of Contrast Media to Pregnant or Potentially . V6 – 2008. 75 Pregnant Patients 16. Administration of Contrast Media to Breast-Feeding Mothers . V6 – 2008 . 79 Table 1 – Indications for Use of Iodinated Contrast Media . V6 – 2008 . 81 Table 2 – Organ or System-Specific Adverse Effects from the Administration . V7 – 2010 . 82 of Iodine-Based or Gadolinium-Based Contrast Agents Table 3 – Categories of Reactions . V7 – 2010 . 83 Table 4 – Management of Acute Reactions in Children . V7 – 2010 . 84 Table 5 – Management of Acute Reactions in Adults . V6 – 2008 . 86 Table 6 – Equipment for Emergency Carts . V6 – 2008 .
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Severe Aseptic Meningitis with Hydrocephalus Following Iotrolan Myelography: a Case Report
    대 한 방 사 선 의 학 회 지 1993 ; 29 (3) : 391 ~393 Journal of Korean Radiological Society, May, 1993 Severe Aseptic Meningitis with Hydrocephalus Following Iotrolan Myelography: A Case Report Jae Hyoung Kim, M.D., Choong Kun Ha, M.D.*, In Oak Ahn, M.D. Dψartmeη t 0/ Diagnostic Radiology, Gyeongsang National University, College 0/ Medicine - Abstract- A case of severe aseptic meningitis with communicating hydrocephalus following iotrolan myelography is presented. The patient’s condition improved veη quickly after corticosteroid therapy. Rapid improvement and absence of pathogenic organisms in the CSF cu\ture strongly favor an aseptic meningitis. This is the first re­ ported case of aseptic meningitis with the secondaη development of hydrocephalus caused by iotrolan myelography Index Words: Contrast media, complications 10.448 Myelography, complications 30.446, 30.1222 Aseptic meningitis as a complication of derwent cervica1 myelography using lumbar myelography has been reported verγ rarely (1 -3) puncture technique because of persistent pares­ since metrizamide was replaced with new non­ thesia in both upper extremities. Before instilla­ ionic contrast media such as iopamid이, iohexol tion of 15ml of iotrolan (Isovist, Schering AG, and iotrolan, Iotrolan is a new contrast medium Berlin; 240mg Ij ml), the patient did not have with a non-ionic dimer of triiodinated benzene any signs or symptoms of meningitis. The cere­ ring. Recently we have experienced a severe brospinal fluid (CSF) obtained during the proce­ aseptic meningitis with hydrocephalus developed dure was c1ear. Mter myelography, the patient after iotrolan myelography. Only one case of rested in a supined position with the head elevat­ 0 mild aseptic meningitis associated with iotrolan ed 15-30 • myelography was reported in 1991 (4).
    [Show full text]